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Abstract
Background: The Rett Syndrome (RTT) brain displays regional histopathology and volumetric reduction, with frontal 
cortex showing such abnormalities, whereas the occipital cortex is relatively less affected.
Results: Using microarrays and quantitative PCR, the mRNA expression profiles of these two neuroanatomical regions 
were compared in postmortem brain tissue from RTT patients and normal controls. A subset of genes was differentially 
expressed in the frontal cortex of RTT brains, some of which are known to be associated with neurological disorders 
(clusterin and cytochrome c oxidase subunit 1) or are involved in synaptic vesicle cycling (dynamin 1). RNAi-mediated 
knockdown of MeCP2 in vitro, followed by further expression analysis demonstrated that the same direction of 
abnormal expression was recapitulated with MeCP2 knockdown, which for cytochrome c oxidase subunit 1 was 
associated with a functional respiratory chain defect. Chromatin immunoprecipitation (ChIP) analysis showed that 
MeCP2 associated with the promoter regions of some of these genes suggesting that loss of MeCP2 function may be 
responsible for their overexpression.
Conclusions: This study has shed more light on the subset of aberrantly expressed genes that result from MECP2 
mutations. The mitochondrion has long been implicated in the pathogenesis of RTT, however it has not been at the 
forefront of RTT research interest since the discovery of MECP2 mutations. The functional consequence of the 
underexpression of cytochrome c oxidase subunit 1 indicates that this is an area that should be revisited.
Background
Rett syndrome (RTT) is a neurodevelopmental disorder
and a leading cause of severe intellectual disability in
females [1]. Distinguishing features of RTT include a loss
of previously acquired skills such as communication, pur-
poseful hand movements and mobility, as well as deceler-
ation of head growth, seizures, and the development of
characteristic stereotypic hand wringing.
One of the most prominent neuropathological features
of RTT is the impairment of normal neuronal develop-
ment, primarily at the synapse with a disruption to the
normal development of axodendritic connections. There
is a decrease in the size of the RTT brain which is par-
tially explained by a decrease in the size of individual
neuronal cell bodies, an increase in the packing density of
neurons [2], possibly an absence of specific neuronal pop-
ulations [3] and a decrease in dendritic arborization [4].
Additionally, areas of 'naked' dendritic spines are
observed on pyramidal neurons of layer II and III in the
frontal cortex [5].
The RTT neuropathology manifests in specific regions
of the brain. The shortening and thickening of dendritic
branches are observed in the same brain regions that have
a decreased volume, for example layers III and V of the
frontal, motor and inferior temporal regions, whereas the
dendrites of the occipital cortex are comparatively less
affected [4].
A diagnosis of RTT is typically made on the evolving
clinical phenotype, although most cases have a genetic
basis and are caused by mutations in the X-linked
MECP2  gene (Methyl-CpG Binding Protein 2) [6].
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MeCP2 has been thought to be a transcriptional repres-
sor that acts by binding to methylated CG dinucleotides
i n so me  g e ne  pr o mo t er s, u lt im a t e ly  ca us ing  chr om a t in
compaction leading to gene silencing. More recent stud-
ies suggest that it may also mediate splicing [7], may be
involved in the higher order organization of chromatin
architecture [8], and in some circumstances can act as a
transcriptional activator [9].
A small subset of atypical cases with a RTT-like pheno-
type, characterized by the early onset of seizures, is asso-
ciated with mutations in CDKL5 (Cyclin-Dependent
Kinase-like 5) [10-12], whilst some individuals with the
congenital RTT variant have mutations in the FOXG1
(forkhead box protein G1) gene [13], and still others
remain genetically undefined.
The localization of MeCP2 to the postsynaptic region
[14] as well as the nucleus, coupled with the possibility
that more than one gene locus is affected, suggests that
dysfunction of more than one molecular pathway may
contribute to the neurological phenotype, and these path-
ways could involve abnormal transcription and/or synap-
tic transmission.
In order to gain an insight into the molecular pathways
that may be affected in RTT, it is important to determine
the genes whose transcription patterns are altered.
Recent studies have uncovered a number of these genes
in frontal cortices of human [15], human non-clonal [16]
and clonal [17] lymphoblast cell lines, human clonal
fibroblasts [18], and various Mecp2 mouse models [9,19-
22]. Some genes have been found to be under the direct
transcriptional control of MeCP2 and so the downstream
effect of this misregulation offers clues as to the molecu-
lar basis of the severe neurological deficit that is observed
in RTT.
In this study we capitalized on the observation that
RTT pathology is predominates in specific neuroanatom-
ical regions of the brain. cDNA microarray analysis
uncovered a number of genes that were abnormally
expressed in the frontal cortex, but not in the occipital
cortex of RTT patients. Using RNA interference, the dif-
ferential expression of these genes was confirmed in vitro
to result from a deficiency in MeCP2. The direct interac-
tion between MeCP2 and the promoter of some of these
genes was confirmed by chromatin immunoprecipitation
(ChIP). In addition, the functional consequence of the
differential expression of one of the genes, cytochrome c
oxidase subunit 1, was evaluated.
Results
Differentially expressed genes in the frontal cortex of Rett 
syndrome brains
Control brain samples were (unfortunately) not age-
matched (age range 31 - 52 yr; age range of RTT patients
4 - 21 yr). At the time the study was performed, we were
unable to access age-matched controls from Australia or
the USA. We acknowledge that expression patterns may
change with age, however, the genes that were analyzed
following initial microarray analysis were also (1) differ-
entially expressed in an in vitro RNAi-mediated knock-
down system and (2) differentially expressed between the
frontal and occipital cortex of the individual RTT brain
samples, independent of any comparison with the control
brain samples. It should be noted that after careful con-
sideration it was decided that this was a unique opportu-
nity to be able to utilize these postmortem samples that
we had available to us, however it was obvious to us from
the outset that using postmortem brain samples of differ-
ent ages, was a shortcoming of the study.
The frontal cortex is one of the brain regions in RTT
that displays the characteristic histopathology associated
with this disorder. In order to establish if there is abnor-
mal expression of a subset of genes in the RTT frontal
cortex, we examined and compared mRNA expression
profiles between the RTT and control frontal and occipi-
tal cortices. Four sets of six microarray experiments were
conducted (Figure 1). The double arrows represent co-
hybridization of the samples at each end of the arrows.
For example, six individual RTT frontal cortices were co-
hybridized with six individual control frontal cortices.
Based on this experimental design differential expres-
sion between: (a) the RTT frontal cortex and control
frontal cortex would possibly be due to individual varia-
tion or could be contributing to RTT pathology; (b) the
RTT frontal cortex and RTT occipital cortex would possi-
bly be due to normal expression differences that occur
between these brain regions or could be contributing to
RTT pathology, and (c) the control frontal cortex and
control occipital cortex would possibly be due to normal
expression differences that occur between these brain
Figure 1 Microarray experimental design. Four sets of six microar-
ray experiments were conducted. The double arrows represent co-hy-
bridization of the samples at each end of the arrows. Six individual RTT 
frontal cortices were co-hybridized with six individual control frontal 
cortices. For example, the frontal cortex of patient RTT1 was compared 
with the occipital cortex of RTT1. Additionally, where the frontal cortex 
of a RTT sample was compared to the frontal cortex of a control sam-
ple, the comparison between the occipital cortices was conducted be-
tween the same samples. For example RTT1 frontal cortex vs. Con4 
frontal cortex, RTT1 occipital cortex vs. Con4 occipital cortex. Each ex-
periment was repeated and the fluorescent cyanine dyes were re-
versed.
(n=6)
(n=6) (n=6)
(n=6)
Control occipital cortex Control frontal cortex
RTT occipital cortex RTT frontal cortexGibson et al. BMC Neuroscience 2010, 11:53
http://www.biomedcentral.com/1471-2202/11/53
Page 3 of 16
regions. Using a subtractive method, genes that were
exclusively differentially expressed in the RTT frontal
cortex were determined as those that were differentially
expressed in (a) and (b), but not in (c). Genes that were
differentially expressed between the RTT occipital cortex
and control occipital cortex were considered to be due
mostly to individual variation as this region appears to be
spared the reduction in dendritic trees [4] and volume
that is observed in other regions of the RTT brain.
Samples were evaluated on an individual basis, RNA
samples were not pooled.
The number of transcripts that reached 'cut-off' for
each set of analyses were those that were expressed above
minimal pixel intensity, and were therefore considered to
be expressed in the brain samples analyzed (Table 1).
Those that were considered differentially expressed
either by 'fold-change' analysis or by SAM analysis were
determined and the genes of interest in the group that
overlapped these two types of analysis are listed in Table
2. The expression of these genes was verified using quan-
titative reverse transcription (qRT)-PCR.
qRT-PCR was performed using new RNA extractions
taken from the same tissue as that subjected to microar-
ray analysis. CLU, CO1, CRMP1 and DNM1 were each
differentially expressed in the RTT frontal cortex when
compared to the RTT occipital cortex (p = 0.047, 0.024,
0.045 and 0.004, respectively) AND when compared to
the control frontal cortex (p = 0.042, 0.024, 0.049 and
0.048, respectively; Figure 2b, c, d and 2e). Each was dif-
ferentially expressed in the same direction as in the
microarray analysis. Interestingly, DNM1  was upregu-
lated in the RTT frontal cortex compared to the RTT
occipital cortex (p = 0.004), and compared to the control
frontal cortex (p = 0.048) however, the expression in the
RTT occipital cortex was also significantly lower than the
control occipital cortex (p = 0.015), suggesting that it was
downregulated in the RTT occipital cortex. APLP1 was
significantly upregulated in the RTT frontal cortex com-
pared to the control frontal cortex (p = 0.020). Both
GNB1  and  GDI1  were significantly differentially
expressed in the RTT frontal cortex compared to the RTT
occipital cortex (p = 0.026 and 0.045, respectively). GDI1
appeared to be expressed less in the RTT frontal cortex
compared to the control frontal cortex however this was
not statistically significant. EML2,  HMN1  and  RTN3
were not significantly differentially expressed by qRT-
PCR, even though EML2 and RTN3 showed an expres-
sion trend similar to that observed in the microarray
experiments.
These data indicate that a subset of genes is (on aver-
age) differentially expressed in the frontal cortex of RTT
patients. In summary, CLU,  CO1,  CRMP1  and  DNM1
were specifically differentially expressed in the RTT fron-
tal cortex compared to RTT occipital cortex and control
frontal cortex, APLP1  was specifically differentially
expressed in the RTT frontal cortex compared to the con-
trol frontal cortex and GDI1 and GNB1 were differentially
expressed in the RTT frontal cortex when compared to
the RTT occipital cortex. EML2, HMN1 and RTN3 were
not differentially expressed.
DNMI, GNBI, CO1 and CLU are differentially expressed 
following in vitro RNAi-mediated MeCP2 knockdown
To provide more specific evidence that reduced expres-
sion or function of MeCP2 is responsible for the altered
mRNA expression noted in the microarray experiments,
RNAi was used to knockdown MeCP2 in vitro. A 21 base
pair dsRNA construct that targeted exon 3 of MECP2 was
Table 1: Summary of transcripts showing differential expression.
Comparison Number of transcripts that passed 'cut-off' Number of differentially expressed transcripts
Fold-change SAM analysis Overlap
RTT fc vs. CON fc 11,812 34 891 15
RTT fc vs. RTT oc 9,334 46 13 9
RTT oc vs. CON oc 9,355 21 0 -
CON fc vs. CON oc 10,087 13 19 4
The number of genes that passed cut-off were those that were expressed (pixel intensity of greater than 200 in one channel) and undistorted 
(not 'flagged') in each group of 6 experiments. The number of genes that was deemed significantly differentially expressed is listed for the 
'fold change' (1.5 fold change) and the SAM analysis comparison. fc = frontal cortex; oc = occipital cortex. A gene that was differentially 
expressed between RTT fc vs. CON fc AND RTT fc vs. RTT oc, and not in the CON fc vs. CON oc was considered for further analysis. Column 
labeled 'overlap' contains the number of transcripts that were differentially expressed in both the fold-change and the SAM analysis.Gibson et al. BMC Neuroscience 2010, 11:53
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Table 2: Differentially expressed genes in the RTT frontal cortex (microarray analysis).
GENBANK ACC # GENE NAME GENE SYMBOL CHR FUNCTION UP OR DOWN 
REGULATED
(average of 
comparisons)
H14069 Amyloid beta (A4) 
precursor-like protein 1
APLP1 19q13.1 Enhancer of neuronal apoptosis UP 2.0
SD 0.47
SEM 0.24
W68191 Clusterin
(apolipoprotein J)
CLU 8p21-p12 Extracellular molecular 
chaperone
UP 1.6
SD 0.12
SEM 0.06
H30899 Collapsin response 
mediator protein 1
CRMP1 4p16.1-p15 Part of semaphorin signal 
transduction pathway
UP 2.6
SD 0.14
SEM 0.08
BE879779
BM888296
BM842146
Cytochrome c oxidase 
subunit I
CO1 M Mitochondrial respiratory chain DOWN 3.3
SD 0.61
SEM 0.27
H51542 Dynamin I DNMI 9q34 Produces microtubule bundles. 
Binds and hydrolyzes GTP. 
Vesicular trafficking
UP 2.0
SD 0.63
SEM 0.31
BE513417 Echinoderm microtubule 
associated protein like 2 
(Homo sapiens)
EML2 19q13.32 Modifies the assembly dynamics 
of microtubules
DOWN 1.9
SD 0.05
SEM 0.02
AL565619 GDP dissociation inhibitor 1 GDI1 Xq28 Regulates the GDP/GTP 
exchange
UP 1.78
SD 0.33
SEM 0.17
H14897 Guanine nucleotide binding 
protein (G protein), beta 
polypeptide 1
GNBI 1p36.33 Integrates signals between 
receptors and effector proteins
UP 2.5
SD 0.90
SEM 0.45
BG167084
BM783962
16S ribosomal RNA/
Humanin
HMN M* Potential role in neurons via a 
putative cell-surface receptor 
through which it exhibits 
neuroprotective activity
UP 2.1
SD 0.34
SEM 0.17
R52851 Reticulon 3 RTN3 11q13 Blocks access of BACE1 (Beta-
site APP-cleaving enzyme 1) to 
APP (amyloid precursor protein) 
within neurons
UP 2.5
SD 0.82
SEM 0.41
These genes were differentially expressed in the RTT frontal cortex when compared to expression in the RTT occipital cortex and the control 
frontal cortex. N.B. The value given for differential expression (either UP or DOWN) refers to the average of the experiments; SD = standard 
deviation; SEM = standard error of the mean; M = mitochondrial.
* This sequence is 99% identical to 16S ribosomal mitochondrial RNA, and also to some nuclear encoded cDNAs.Gibson et al. BMC Neuroscience 2010, 11:53
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Figure 2 Expression of genes of interest in RTT and control samples, individual samples. The expression of genes of interest was measured by 
quantitative RT-PCR. Expression of each transcript was evaluated in six RTT and six control frontal and occipital cortices, and normalized to the expres-
sion of GAPDH in the same sample. RTT = Rett syndrome; CTL = control; FC = frontal cortex and OC = occipital cortex. Samples that were expressed 
more than 10-fold higher than housekeeping genes were serially diluted and multiple dilutions were analyzed. The Y-axis shows the ratio of the tran-
script of interest normalized against GAPDH (a) APLP1 mRNA expression levels in RTT FC were significantly higher than in control FC (p = 0.02), but 
not compared to RTT OC (p = 0.06); (b) CLU mRNA expression levels in RTT FC were significantly higher than in control FC (p = 0.042) and RTT OC (p 
= 0.047); (c) CO1 mRNA expression levels in RTT FC were significantly lower than in control FC (p = 0.024) and RTT OC (p = 0.024); (d) CRMP1 mRNA 
expression levels in RTT FC were significantly higher than in control FC (p = 0.049) and RTT OC (p = 0.045); (e) DNMI mRNA expression levels in RTT FC 
were significantly greater than in the control frontal cortex (p = 0.048) and RTT OC (p = 0.004), however expression in the RTT OC was significantly 
lower than in the control OC (p = 0.004); (f) EML2 mRNA expression levels in RTT FC were not significantly different to the RTT OC (p = 0.062), or the 
control FC (p = 0.213); (g) GDI1 expression in the RTT FC was significantly greater than the RTT OC (p = 0.045), but not compared to expression in the 
control FC (p = 0.14); (h) GNBI mRNA expression in the RTT FC was significantly greater than in the RTT OC (p = 0.026), but not compared to the control 
OC (p = 0.164); (i) HUM mRNA expression in the RTT FC was not significantly greater than in the RTT OC (0.064) or the control FC (p = 0.092); (j) RTN3 
mRNA expression in the RTT FC was not significantly greater than in the RTT OC (p = 0.148) or the control FC (p = 0.378).
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transfected into cultured SH-SY5Y cells. Knockdown effi-
ciency was evaluated by assessing MECP2 mRNA (qRT-
PCR) and protein (western blot analysis) expression.
Time course experiments were conducted to evaluate the
level and duration of the knockdown (Figure 3a and 3b).
mRNA expression was consistently reduced by 75% to
80% with the greatest reduction observed at Day 3 - 4.
Protein expression was consistently lowest at Day 3 - 4
with greater than 90% knockdown, and with complete
recovery to normal levels between Day 7 and Day 14.
CO1, CLU, DNMI and GNBI were amongst the tran-
scripts of interest that had statistically significant differ-
ential expression in the RTT frontal cortex. CLU  and
CO1 were of interest because of known associations with
neurological disorders, and CO1 because of the described
mitochondrial abnormalities observed in RTT. DNMI
and  GNBI  were of interest because of their respective
roles in endocytosis and signal transduction in neurons.
The differential expression of these genes in RTT could
be the result of a direct interaction of MeCP2 with these
genes or it could be due to the interaction of MeCP2 with
a gene upstream in a common pathway. We investigated
the expression of these genes following RNAi-mediated
knockdown of MeCP2 in SH-SY5Y cells. The expression
pattern of these genes was analyzed over a fourteen day
period, either with or without retinoic acid-induced dif-
ferentiation of SH-SY5Y cells (Figure 4). Time course
experiments were conducted twice and qRT-PCR mea-
surement of the expression of each gene was conducted
in triplicate on two occasions for each time course exper-
iment. The expression levels of each gene were normal-
ized to the expression levels of GAPDH, and therefore
values on the Y axis reflect a ratio of expression of the
gene of interest to the expression of GAPDH in the same
sample. The expression of GAPDH  is unaffected by
MeCP2 knockdown (data not shown).
CLU mRNA expression in undifferentiated cells gradu-
ally fell throughout the 14 days (Figure 4a). The reduction
was less pronounced in the MeCP2 knockdown sample
however (1.9-fold reduction), than in the control (11.5-
fold reduction). In the differentiated samples CLU
expression increased in the MeCP2 knockdown sample
(1.4-fold), whilst it fell in the control sample (5-fold).
Therefore, the absence of MeCP2 in differentiated cells
caused an uncharacteristic increase in CLU expression. It
is not entirely clear why CLU showed a general trend
d o w n w a r d  i n  u n d i f f e r e n t i a t e d  c e l l s .  E x p r e s s i o n  i n  S H -
SY5Y cells was evaluated a number of times and for up to
21 days (data not shown). It repeatedly showed a down-
ward trend which would plateau after 14 DIV. As clus-
terin is a secreted protein that binds membranes and
possibly inhibits apoptosis by interfering with BAX acti-
vation in mitochondria [23], it is possible that the initial
higher levels of expression were a consequence of the in
vitro culturing of the cells and the initial stress on the
cells following passaging, whilst they adhere to the cul-
ture dish and become confluent.
Undifferentiated cells showed a gradual increase in
CO1 mRNA expression in control samples (2.2-fold by
Day 7, Figure 4b). Following MeCP2 knockdown how-
ever, there was a 1.5-fold reduction of CO1 expression at
Day 4 and Day 5. Differentiation of SH-SY5Y cells caused
a dramatic rise in CO1 expression in the control sample
(8.7-fold), however this was not reflected in MeCP2
knockdown sample, where by Day 4 CO1  expression
increased only 2.4-fold. Thus, it appeared that a normal
Figure 3 RNAi-mediated knockdown of MECP2. MECP2/MECP2 expression following RNAi-induced MeCP2 (e1 and e2) knockdown. Cells were har-
vested at time points over a 2-week period. (a) MECP2 mRNA expression in SH-SY5Y cells. Transcript levels were assessed by Real-Time qPCR and com-
pared to the expression of GAPDH in each sample. MECP2 expression was quantitated at each time point, and presented as a percentage of the 
expression level at day 0, which was set at 100%. The knockdown sample (sh-MECP2) displays a 75-80% reduction in MECP2 expression when com-
pared to the negative control (mut-shMECP2) or to untreated cells (data not shown). MECP2 mRNA expression in the negative control remained above 
95% greater than all time points; (b) MECP2 protein expression is reduced by 90% at Day 3. Each protein sample was divided in two and loaded onto 
duplicate gels, one immunoblotted with α-MECP2 and the other with α-actin.
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Figure 4 Expression of CO1, CLU, DNMI and GNBI in vitro following RNAi-mediated knockdown of MECP2. mRNA expression levels of selected 
genes of interest were assessed following RNAi-mediated knockdown of MECP2. Expression levels were evaluated in SH-SY5Y cells with or without 
RA-induced differentiation over a 14-day period. Expression levels of genes of interest were compared to that of GAPDH mRNA expression in the same 
sample. (a) Clusterin expression levels were higher in MECP2 knockdown samples than in controls in both differentiated and undifferentiated cells. 
This was more pronounced in differentiated cells where an increase in clusterin expression above basal levels was observed; (b) Cytochrome c oxidase 
(subunit 1) levels remained at basal levels following MECP2 knockdown in both undifferentiated and differentiated cells, whereas there was approxi-
mately a two hundred fold increase in CO1 expression levels in the control cells; (c) Dynamin I shows an increase in expression levels following MECP2 
knockdown at Day 4, however this returned to basal levels at Day 6; (d) An increase in Guanine nucleotide binding protein β-polypeptide was ob-
served in differentiated cells in both the MECP2 knockdown sample and the control sample, however this was 2-fold greater in the MECP2 knockdown 
sample.
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increase in CO1 expression during cellular differentiation
was suppressed by MeCP2 knockdown.
DNMI mRNA expression remained steady in both the
differentiated and undifferentiated control samples (Fig-
ure 4c). However, following MeCP2 knockdown, there
was a 2-fold increase in the undifferentiated sample (Day
4) and 3-fold in the differentiated sample. In both cases
expression levels returned to basal levels by Day 7.
GNBI mRNA expression remained steady in the undif-
ferentiated control sample and then increased 46-fold fol-
lowing differentiation (Figure 4d). Following MeCP2
knockdown, GNBI expression increased 2.6-fold in undif-
ferentiated samples and 77-fold in differentiated samples.
Therefore, a significant increase in GNBI expression was
observed in the absence of MeCP2.
Each of these genes showed differential expression fol-
lowing in vitro MeCP2 knockdown in the same direction
(up or down regulated) observed in the patient brain
s a m p l e s .  T h i s  d i f f e r e n t i a l  e x p r e s s i o n  w a s  m o r e  p r o -
nounced following the differentiation of the SH-SY5Y
cells into a neuron-like phenotype. These results suggest
that the abnormal expression of CLU, CO1, DNMI and
GNBI is due to a lack of MeCP2.
MeCP2 associates with promoter regions of CLU, CRMP1, 
DNMI and GNBI
The upregulation of CLU,  DNMI,  GNBI  and in some
analyses, CRMP1, was further investigated by evaluating
a potential association between MeCP2 and sequences
within the promoters of these genes. CO1 was not inves-
tigated in this experiment due to the fact that mitochon-
drially-encoded genes lack CpG methylation, and it is
therefore not likely to be under the direct transcriptional
control of MeCP2. For differentiated and undifferentiated
SH-SY5Y, proteins were cross-linked to genomic DNA,
followed by shearing of the chromatin, and immunopre-
cipitation with an antibody specific for MeCP2 and BAF
57. After reversing the protein/DNA cross-links, the
immunoprecipitated DNA was purified and subjected to
quantitative real time PCR. Clusterin and CRMP1 inter-
estingly showed minimal association with MeCP2 in
undifferentiated cells. However, following RA-induced
differentiation of the cells to a mature neuron-like pheno-
type, MeCP2 showed greater association with these genes
(Figure 5a and 5b). In contrast there was a strong associa-
tion between DNMI  and  GNBI  promoter regions with
MeCP2 (Figure 5c and 5d) in differentiated and undiffer-
entiated cells. The ChIP assay clearly shows that MeCP2
is associated with BDNF promoter in Human SH-SY5Y
cells (Figure 5e).
Cytochrome c oxidase activity is reduced following MeCP2 
knockdown
Down-regulation of CO1  expression in both the RTT
frontal cortex postmortem tissue and in vitro following
MeCP2 knockdown suggests mitochondrial dysfunction
may contribute to RTT neuropathology. This gene is of
specific interest because of reports of mitochondrial
abnormalities in RTT [24-29]. To determine if down-reg-
ulation of the mitochondrially-encoded, largest subunit
of cytochrome c oxidase, CO1, was associated with a
functional abnormality of cytochrome c oxidase (COX),
COX enzyme activity was assayed by measuring the rate
of oxidation of reduced cytochrome c following in vitro
MeCP2 knockdown in SH-SY5Y cell line three days post-
transfection with the MECP2 dsRNA knockdown oligo-
nucleotide, or the control.
The reduction in cytochrome c oxidase activity at Day 3
in the MECP2-deficient system (Figure 6) was statistically
significant, being approximately 60% of that observed in
the untreated sample at Day 0 and the control sample at
Day 3. This therefore suggests that the down-regulation
of CO1 in the frontal cortex of RTT brains may be func-
tionally significant, as COX activity is reduced, which
potentially could impact on the efficiency of ATP genera-
tion in the brain.
Discussion
The discovery that mutations in MECP2 are responsible
for most cases of RTT has led researchers to search for
transcriptional targets and misregulated expression of
genes. A profile of aberrantly expressed genes or classes
of genes has slowly emerged, and subsequent down-
stream functional analyses of these genes are shedding
light on the impact that their abnormal expression has on
the pathology of RTT. Various mRNA microarray or dif-
ferential display studies in human postmortem tissue
[15], Mecp2-mutant mice [9,19-22,30], patient fibroblast
[18], lymphoblastoid [16,18] and lymphocyte cells [17],
and neuroblastoma (SH-SY5Y) cells in which MECP2 has
been knocked down [30], have revealed that MeCP2 tran-
scriptionally controls a wide range of functionally distinct
genes.
Our aim was to expand the repertoire of genes that are
aberrantly expressed in the RTT brain. To achieve this,
we took the novel approach of evaluating differential
mRNA expression between an affected and an unaffected
brain region in MECP2 mutation-positive RTT patient
postmortem tissue samples while also comparing mRNA
expression in diseased and healthy tissue. We acknowl-
edge that a potential limitation of our study is that at the
time of this study we were unable to obtain equivalent
age-matched control samples. It could be argued that the
observed differences are a consequence of the develop-
mental and aging processes or could be an epiphenome-
non as a result of the disease process. However, we feel
that the conclusions drawn in this exploratory phase of
the study were valid for several reasons. Firstly, we
applied very stringent criteria in selecting genes for fur-
ther study, including the requirement that for a gene to beGibson et al. BMC Neuroscience 2010, 11:53
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Figure 5 Chromatin immunoprecipitation of MECP2. The association of MECP2 with the promoter regions of BDNF, CRMP1, DNMI, GNBI and CLU 
in undifferentiated and differentiated SH-SY5Y cells. The DNMI and GNBI promoter sequences displayed no difference in binding with MeCP2 in both 
undifferentiated and differentiated cells. Results are the mean +/- SEM of six replicates. The ChIP experiments were normalized to the input DNA.
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flagged as potentially significant it had to be differentially
expressed in at least 5 out of the 6 relevant microarray
data sets. Secondly, comparison of microarray data sets of
different regions in the same subject yielded results that
were consistent with our central hypothesis, namely that
brain region-specific differences in gene expression
would allow us to identify genes of potential biological
relevance to the RTT neurodevelopmental phenotype.
Thirdly, the subset of genes we chose for further analysis
all showed differential expression in our RNAi-mediated
knockdown system in the same direction as was seen in
the microarray experiments. Finally, enzymatic studies of
cytochrome c oxidase in the RNAi treated SH-SY5Y cells
confirmed that the abnormalities seen at the RNA level
were of functional significance at the protein level.
Only one other microarray study has used RTT patient
brain samples as the source material [15]. There were,
however, a number of limitations of this study, including
difficulties in comparing expression data obtained by
using different microarray procedures, which differed
significantly in four ways - substrates (eg nylon filters ver-
sus glass slides), types of labels (radioactivity versus fluo-
rophores), numbers of cDNA clones (eg 597 clones for
one type of array versus ~7000 clones for another), and
the threshold for delineating differential expression. For
our studies we used only one array platform, containing
around 19,000 transcripts, and employed very stringent
filtering criteria with the aim of having a low false discov-
ery rate of less than 0.6%. Using this approach we identi-
fied only a small number of genes showing altered
expression in the frontal cortex of RTT patients, and our
in vitro studies of a subset of these genes recapitulated
our microarray results.
Recognized, but little studied, findings in RTT patients
are morphological abnormalities of mitochondria
[24,25,27], functional defects of the mitochondrial respi-
ratory chain [26,29], and evidence of increased oxidative
stress [28]. In addition, some of the non-neurological
manifestations of RTT have been seen in patients with
primary respiratory chain disorders, including short stat-
ure, myopathy, cardiac arrhythmias, and intestinal
pseudo-obstruction [31]. However, the contribution of
these functional abnormalities of the respiratory chain to
the pathogenesis of RTT remains unclear. At a molecular
level, an association between MeCP2 and the promoter of
ubiquinol-cytochrome c reductase core protein 1 has
been demonstrated (Uqcrc1) with subsequent up-regula-
tion of this gene and mitochondrial respiratory chain dys-
function in Mecp2-null mice [21], as noted above. Here
we show that cytochrome c oxidase subunit 1 expression
was down-regulated exclusively in the frontal cortex of
the RTT brain. This down-regulation was a consequence
of MeCP2 deficiency (by RNAi analysis) and manifested
as a decrease in COX enzyme activity. These two findings
suggest that a defect in MeCP2 activity is likely to result
in significant dysfunction of the mitochondrial respira-
tory chain in the brain and possibly other organs, which
could contribute to the clinical abnormalities seen in
RTT patients. It should be noted however that CpG
methylation is absent in mitochondrially-encoded genes.
Therefore, it is not likely that cytochrome c oxidase sub-
unit 1 is under the direct transcriptional control of
MeCP2, but may be affected as a consequence of a direct
interaction of MeCP2 and a nuclear-encoded component
of the processes responsible for mitochondrial DNA rep-
lication, transcription or translation, or direct interaction
of MeCP2 with a nuclear-encoded protein that plays a
role in maintaining the structure and stability of the COX
protein complex.
Dynamin I was upregulated in the frontal cortex of the
RTT brain, and we have demonstrated in vitro that it was
upregulated as a result of MeCP2 knockdown, and that
the promoter region of dynamin I associated with
MeCP2. Dynamin I is a large GTPase that is involved syn-
aptic vesicle endocytosis. Specifically, it assembles
around the invaginated clathrin-coated pit and pinches
the vesicle from the plasma membrane [32]. Other indi-
cations of abnormalities in synaptic transmission in RTT
have come from studies investigating the aberrant expres-
sion of glutamate receptors such as NMDA and AMPA
receptors at excitatory synapses [33,34], and associated
impairment of both long term potentiation (LTP) and
depression (LTD) [34], and by the correction of abnor-
malities in LTP when Mecp2 deficiency is reversed in a
mouse model of RTT [35]. NMDA receptor expression is
decreased in RTT and interestingly, the internalization of
this receptor is clathrin-mediated and is facilitated by a
Figure 6 Cytochrome c oxidase activity following RNAi-mediated 
knockdown of MECP2. Cytochrome c oxidase (COX) activity was de-
termined as a first order rate constant and expressed as rate/minute/
mg protein, whilst the specific activity of the mitochondrial matrix en-
zyme citrate synthase (CS) was determined and expressed as nmol/
minute/mg protein. COX was normalized to CS activity to take into 
consideration any variation in mitochondrial numbers, and is ex-
pressed as a ratio. Three days post-transfection, when MECP2 knock-
down is greatest, cytochrome c oxidase activity is just 60% of that 
observed in the untreated sample at Day 0 (p = 0.005) and the control 
sample at Day 3 (p = 0.015). KD = knockdown.
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postsynaptic member of the dynamin family, dynamin 2
[36]. Additionally, it has been demonstrated that synaptic
activity can induce phosphorylation of MeCP2 which
subsequently leads to gene transcription [37]. The
increase in the expression of dynamin I in the frontal cor-
tex of RTT patients may manifest as abnormal rates of
synaptic vesicle cycling which adds another dimension to
the idea that anomalous synaptic transmission is contrib-
uting to the severe cognitive impairment in RTT.
The regulation of expression and function of the glyco-
protein clusterin remains incompletely defined. It is asso-
ciated with apoptosis, and whilst it is thought to promote
tumor progression in cancer through Bax interaction
[23], it possibly suppresses beta-amyloid deposition in
Alzheimer disease [38]. Upregulation of clusterin expres-
sion is not only associated with amyloid deposits in
Alzheimer disease [39] but also with various other neuro-
logical disorders. Increased expression is associated with
deposition of prion protein in transmissible spongiform
encephalopathies [40], with status epilepticus [41] and
following cerebral ischemia where it is associated with
tissue remodeling [42]. In the brain it is expressed in spe-
cific neuronal populations of cells in the hippocampus
and cerebellum. These are regions of the brain that have
been implicated in dysfunction in RTT at a histological
level, and increasing evidence now also suggests that
these regions are also dysfunctional at a molecular level.
In this study, clusterin was upregulated in the frontal cor-
tex of RTT brains and this upregulation was the result of
MeCP2 deficiency as demonstrated by in vitro RNAi-
mediated knockdown of MeCP2. In addition, the CpG-
rich promoter region of clusterin associates with MeCP2,
and it is interesting to note that it has previously been
shown that expression of clusterin is induced by histone
deacetylase inhibitors [43], raising the possibility that one
mechanism by which MeCP2 mutations may exert their
effect could be by failing to repress transcription through
the interaction of MeCP2 with histone deacetylase. Inter-
estingly, in the Delgado study, clusterin was underex-
pressed in mutant T-lymphocyte clones from RTT
patients [17]. Whether abnormal expression of clusterin
is related to a pro- or anti-apoptotic function is unknown,
but the fact that it is upregulated in a region that displays
a greater level of cellular pathology makes it seem likely
that its role in RTT is not of a neuroprotective nature.
CRMP1 is involved in semaphorin-induced growth
cone collapse during neural development. It was upregu-
lated in the RTT frontal cortex and we showed that
MeCP2 associated with its promoter region in differenti-
ated neuronal cell cultures. In adult mice, CRMP1 is
localized to dendrites of cortical and hippocampal (CA1)
pyramidal neurons [44], where it is possibly involved in
neurite outgrowth and LTP [45]. CRMP1 knockout mice
display abnormal MAP2 staining [45]. Abnormalities in
CRMP1 expression in this study may explain in part the
morphological abnormalities observed in neurons in the
RTT brain whereby there is a decrease in dendritic
arborization.
This study utilized stringent inclusion criteria for dif-
ferentially expressed genes. It can be noted however
(Table 1) that there was a large number of transcripts that
were differentially expressed in some comparisons, but
not in others. It is interesting to note that a number of the
genes that were up- or downregulated in the frontal cor-
tex were also up- or downregulated in other studies.
Another component of the respiratory chain succinate
dehydrogenase (subunit B), EH-domain containing 1
(endocytosis of IGF1 receptors) and amyloid precursor
protein were all differentially expressed in some of the
analyses in this study as well as in the study conducted by
Colantuoni et al. [15]. Genes that were statistically upreg-
ulated in this study (yet didn't have a significant fold
change value) were also upregulated in the Delgardo
study including eukaryotic translation initiation factor 2
subunit 1 alpha, thioredoxin, autism susceptibility candi-
date 2 and COX 15 homolog. MIR (Membrane-associ-
ated ring finger) is a protein linking membrane proteins
to the actin cytoskeleton, PAM (Peptidylglycine alpha-
amidating monooxygenase) catalyzes neuroendocrine
peptides and FHL1 (four and a half LIM domains)
involved in cell growth and differentiation. These tran-
scripts were all differentially expressed in the frontal cor-
tex in this study (SAM analysis) and in RTT-derived
lymphoblastoid cell lines [16]. Additionally, creatine
kinase was upregulated by SAM analysis in the frontal
cortex in this study and in the olfactory proteomic study
[46].
This study has looked at the differential expression of
genes in an area of the RTT brain that displays abnormal
neuronal development. We have found that this differen-
tial expression was reproduced in an in vitro MeCP2
RNAi system. The promoter regions of two of these genes
(DNMI and GNBI) associated with MeCP2 in differenti-
ated and undifferentiated neuron-like cells, whilst two
other genes (CRMP1 and CLU) associated with MeCP2
in differentiated cells only. In addition, downregulation of
CO1 expression manifested as a downregulation of COX
activity of the mitochondrial respiratory chain.
In summary, this study has further contributed to our
understanding of how MeCP2-mediated misregulation of
transcriptional repression of subsets of genes may influ-
ence the pathology in RTT. Of particular importance is
the emerging role of mitochondrial dysfunction as well as
the possibility that specific abnormalities in synaptic
transmission contribute to the disease.
In considering the role of MeCP2-regulated genes high-
lighted in this study, further investigations of the effect of
MeCP2 on apoptosis and/or neuroprotection, respiratoryGibson et al. BMC Neuroscience 2010, 11:53
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chain function, vesicle-mediated endocytosis, and sec-
ondary messenger/cell signaling in the RTT brain may
provide further insight in to the pathophysiology of RTT.
Conclusion
In this study we have used microarray technology to iden-
tify targets of MECP2, the gene responsible for most
cases of the devastating neurodevelopmental disorder
Rett syndrome. This is only the second time that brain
samples from humans with Rett syndrome have been
used in such a study. Using a stringent filtering approach
we have found only a small number of genes show consis-
tent altered expression in the frontal cortex of Rett syn-
drome patients. We provide evidence that Rett syndrome
may in part be due to abnormalities of mitochondrial
respiratory chain function and neuronal vesicle dynam-
ics.
Methods
Patient Samples
Postmortem neural tissue from RTT and gender matched
normal control individuals (Table 3) was obtained from
The Harvard Brain Tissue Resource Center, Boston, USA;
the New South Wales Tissue Resource Centre, Sydney,
Australia; Baylor College of Medicine, Houston, USA,
and The Telethon Institute for Child Health Research,
Perth, Australia. All specimens were retained and used
for research with appropriate written consent from the
families. This research was approved by the Ethics Com-
mittee of the Children's Hospital at Westmead.
None of the RTT or control patients suffered prolonged
agonal states, such as prolonged premortem anoxic
injury, multi-organ failure or coma. RNA integrity was
assessed in nine RTT patient samples and seven were
deemed to have suitably intact RNA for further analysis.
One patient did not have a MECP2 mutation/large dele-
tion and was omitted from the study. Samples from The
Harvard Brain Tissue Resource Center, the New South
Wales Tissue Resource Centre and the Telethon Institute
for Child Health Research were supplied as full thickness
cortical layer. In two instances we received larger coronal
samples from the Baylor College of Medicine. In these
instances, the outer cortical layers were isolated so that
results could be comparable to the other samples. The
results of the initial microarray experiments would there-
fore represent contributions from various outer cortical
layers, and teasing out the subtleties of the contribution
of individual layers would have been lost in this experi-
ment. However, the expression changes that were
observed can be concluded to be an average of these out-
ermost cortical layers.
Microarray studies
Four types of comparisons were made between: (1) the
frontal and occipital cortices of each RTT brain; (2) RTT
frontal cortices and control frontal cortices; (3) frontal
and occipital cortices of each control brain, and (4) RTT
occipital cortices and control occipital cortices.
All microarray experimental details were documented
according to MIAME guidelines and are documented at
MiameExpress (Accession number: E-MEXP-2588) [47].
Microarrays were sourced from the University Health
Network (UHN) Microarray Centre, Ontario, Canada
http://www.microarrays.ca. They were spotted microar-
rays containing 19,008 characterized and unknown
sequence-verified human expressed sequence tags
(ESTs), from I.M.A.G.E. Consortium, printed onto two
Corning® Gamma Amino Propyl Silane II (CMT-GAPS)
glass slides.
Total RNA was extracted from 100 mg of postmortem
brain tissue using Tri Reagent™ (Sigma-Aldrich Inc), fol-
lowing the manufacturer's recommended protocol. The
integrity of RNA was assessed by running approximately
1 μg of total RNA on a 1.2% (v/v) formaldehyde agarose
(FA) gel. Messenger RNA was amplified from total RNA
using a modified version of the Eberwine ("antisense")
RNA amplification protocol [48,49]. First strand cDNA
synthesis from total RNA was conducted using an oligo
d(T)/T7 primer and SuperScript™ II RNase H- Reverse
Transcriptase (Invitrogen™ Life Technologies). Second
strand synthesis was conducted using E. coli DNA Poly-
merase I and RNaseH (Invitrogen™ Life Technologies).
Linear in vitro transcription of mRNA was undertaken
using the MEGAscript™ High Yield Transcription Kit
(Ambion®) according to the manufacturer's instructions.
Amplified mRNA was reverse transcribed and a modified
nucleotide (amino allyl-dUTP) was incorporated in the
following ratio: 25 mM dATP, 25 mM dCTP, 25 mM
dGTP, 15 mM dTTP, 10 mM aa-dUTP. The aa-labelled
cDNA was fluorescently labeled with cyanine 3 (Cy3) or
cyanine 5 (Cy5) monofunctional reactive dyes (Amer-
sham Biosciences Pty Ltd). For subsequent hybridization,
the total number of picomoles of dye incorporated for
each sample was greater than 200 picomoles in a ratio of
less than 80 nucleotides/dye molecules. Microarrays were
scanned on an Axon GenePix® 4000B laser scanner (Axon
Instruments).
Data normalization and partial analysis were carried
out using the Bioconductor libraries of R http://cran.us.r-
project.org/. The raw data from each group of experi-
ments was normalized using a smoothing function, Loess
in the R open-source software package.
Two approaches were taken in order to most accurately
determine differential mRNA expression:
(1) The average fold change was a measure of the rela-
tive expression of the test sample to the control sample.
This was evaluated after a number of stringency criteria
were applied to the data set. Relative hybridization of the
two samples being analyzed had to result in a normaliza-
tion factor of the ratio of the medians between 0.8 andGibson et al. BMC Neuroscience 2010, 11:53
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1.2. All flagged features were removed prior to analysis.
In addition, the absolute hybridization value in either the
red (F635) or green (F532) channels for each spot/feature
was required to exhibit a minimum intensity of 200. To
determine fold change the expression level of each gene
in the sample was divided by the expression level of the
same gene in the control. Any gene with a value of >1.5 or
<0.67 was regarded as differentially expressed. This level
of fold change (1.5) was previously determined by the fol-
lowing: two aliquots of the same batch of RNA from a
postmortem control brain sample were amplified, reverse
transcribed, labeled, hybridized and normalized as
described above. The standard deviation of the data was
calculated to be 0.25, which was interpreted as a 95% con-
fidence level that data with a fold change greater than 1.5
were likely to represent a true change. Six independent
replicate brain tissues were evaluated. A gene that was
differentially expressed in at least 5 microarray data sets
was considered differentially expressed.
(2) Significance Analysis of Microarrays (SAM): SAM
was used to statistically assess expression changes for
each gene (i). The test provides a score (dI) based on the
standard deviation of repeated permutations of the data
http://www.utulsa.edu/microarray/Articles/sam man-
ual.pdf. Data from microarray experiments were assessed
in relation to a response variable (for example, RTT vs.
control). The score generated was indicative of the
strength of the relationship between mRNA expression
and the response variable. A threshold for significance is
denoted as delta, which is arbitrarily set based on a
desired false positive rate (0.05).
Quantitative Reverse Transcription (qRT-PCR)
The expression of genes that were identified in the
microarray experiments as being up or downregulated
were validated by qRT-PCR using a Rotor-Gene™ 3000
Real Time Thermal Cycler. A separate RNA extraction
from each of the same postmortem samples was per-
Table 3: Characteristics of the RTT patient and control brain samples used in this study.
Sample Source UId Sex Age Mutation
nt change aa change domain affected type of mutation
RTT1 HBTRC 4315 F 11 c.763C>T R255X TRD-NLS Nonsense
RTT3 HBTRC 4422 F 12 c.808C>T R270X TRD-NLS Nonsense
RTT4 TICHR NB F 18 c.473C>T T158M MBD Missense
RTT5 TICHR KB F 11 c.316C>T R106W MBD Missense
RTT6 TICHR BC F 21 c.808C>T R270X TRD-NLS Nonsense
RTT9 BCM 93-244 F 4 c.750insC P251fs TRD Frameshift/Truncation
CON4 NSWTRC 88210 F 43
CON5 NSWTRC 88295 F 42
CON6 NSWTRC 88365 F 31
CON7 NSWTRC 88304 F 43
CON8 NSWTRC 9092 F 46
CON10 NSWTRC 12862 F 52
Abbreviations: HBTRC = The Harvard Brain Tissue Resource Center, Boston, USA; NSWTRC = The New South Wales Tissue Resource Centre, Sydney, 
Australia; BCM = Baylor College of Medicine, Houston, USA; TICHR = Telethon Institute for Child Health Research, Perth, Australia; UId = unique 
identifier from original source; MBD = methyl-binding domain; TRD = transcription repression domain; NLS = nuclear localization signal.Gibson et al. BMC Neuroscience 2010, 11:53
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formed as previously described (this RNA was not lin-
early amplified as it was for the microarray experiments).
Each gene of interest was amplified using primers that
spanned an intron and lay close to the 3' end of the gene.
Primers and PCR conditions can be provided on request.
mRNA expression levels of genes of interest were evalu-
ated in both the frontal and occipital cortex of each RTT
and control sample, and normalized to GAPDH expres-
sion from the same sample. Each sample was evaluated in
triplicate within an experiment and three independent
experiments were conducted. A Mann-Whitney U test
was used to test for significance.
In vitro RNA interference (RNAi)
Human SH-SY5Y neuroblastoma cells (ATCC®  CRL-
2266™) were grown to 90% confluence in a 24-well plate
format in D-MEM/F-12 and FBS (Gibco®) at 37°C/5%
CO2.
A dsRNA transcript that targeted a 21 base pair
s e q u e n c e  i n  e x o n  3  o f  MECP2  (shMeCP2; AAGCAT-
GAGCCCGTGCAGCCA; nucleotides 291-311;
NM_004992)  w a s  u s e d  t o  k n o c k d o w n  M e C P 2  i n  S H -
SY5Y cells. This sequence is present in both the
MECP2_e1 and e2 isoforms. The negative (non-silencing)
control RNA transcript targeted a 21 base pair sequence
(mut-shMeCP2; AATTCTCCGAACGTGT CACGT)
that had no homology to the human genome (Qiagen Pty
Ltd).
dsRNA was transfected into SH-SY5Y cells at a 1:6 ratio
of dsRNA:RNAiFect transfection reagent (Qiagen). After
3 days, MeCP2 expression/knockdown was evaluated by
qPCR and Western blot analysis. Cells were differentiated
with 10 μM retinoic acid (RA). Cells were lysed in: 400
mM KCl, 50 mM HEPES, 1.5 mM EDTA, 20% (v/v) glyc-
erol, 0.5% (v/v) NP40, 20 mM sodium fluoride (NaF), 10
mM sodium molybdate, 100 μM sodium ortho-vanadate,
and 1 mM dithiothreitol and protease inhibitors, (1 mM
phenyl-methy-sulphonyl fluoride [PMSF], 0.2 mg/mL
Bacitracin, 0.2 mg/mL Aprotinin, 5 μg/mL Leupeptin and
5 μg/mL pepstatin A). Fifty micrograms of total protein
was run on duplicate 8% SDS-PAGE gels and immunob-
lotted with either mouse anti-actin (1:10,000; kindly
donated by Oncology Research Unit, The Children's Hos-
pital at Westmead) or rabbit anti-MeCP2 (1:500; Peptide:
Auspep, Antibody: Strategic Biosolutions). Primary anti-
bodies were detected with HRP-conjugated sheep anti-
mouse (1:2000; Amersham Biosciences Pty Ltd) or goat
anti-rabbit (1:2000; Santa Cruz) and chemiluminescence.
The film was scanned on a BioRad GS-800 Calibrated
densitometer (BioRad Laboratories) and Quantity One®
4.2.2 software was used to semi-quantitate bands on the
Western blot.
Chromatin Immunoprecipitation
ChIP analysis was performed following the instructions
recommended by the supplier (Upstate Biotechnology)
w i t h  s o m e  m o d i f i c a t i o n s .  B r i e f l y ,  p r o t e i n s  w e r e  c r o s s -
linked to DNA by adding formaldehyde to a final concen-
tration of 1%. 2.5 M Glycine at a final concentration of
125 mM was added to quench formaldehyde cross-link-
ing. Samples were resuspended in SDS lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, Roche
Complete Protease Inhibitor tablet) and sonicated for 15
min, using 30 sec on/off cycle (Diagenode sonicator) to
shear the chromatin. The size of the genomic fragments
after sonication was between 200-500 bp. The soluble
chromatin fraction was incubated overnight at 4°C rotat-
ing, with either: 5 μg anti-MeCP2 [donated by Dr. Peter L.
Jones], Mecp2 (9317 Sigma), 5 μg BAF 57 (donated by Dr
Said Sif) and 5 μg rabbit IgG (Santa Cruz) as a negative
control. Immune complexes were collected with protein
A/G agarose beads and the supernatant fraction kept as
the unbound DNA control. The chromatin-antibody
complex was washed with low salt buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1 and
150 mM NaCl), followed by washes in high salt buffer
(0.1% SDS, 1% TritonX-100, 2 mM EDTA, 20 mM Tris-
HCl pH 8.1 and 500 mM NaCl), lithium chloride buffer
(0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA
and 10 mM Tris-HCl, pH 8.1) and two washes in TE Buf-
fer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The chroma-
tin-bead conjugate was resuspended in freshly prepared
elution buffer (1% SDS, 0.1 M NaHCO3) and incubated at
room temperature, rotating for 30 minutes. The superna-
tant fraction was collected and NaCl added to final con-
centration of 100 mM before phenol/chloroform
extraction. Crosslinks were reversed by incubating at
65°C overnight. Samples were recovered by phenol/chlo-
roform extraction and ethanol precipitation. Specific
primers used for PCR were:
Clusterin: 5'-GTGGCGCTTGTGTAATGTGAA, 3'-TC
ACCACGAATAGCTGTGCTG;
CRMP1: 5'-GCTGGTTCAATGCTAGGATGG, 3'-AC
GTTCTTGTCCCTCCAGGAT
Dynamin1: 5'-AGGAAGCCCATCTGCTCTCC, 3'-GG
GCATCATGGGTGTCGTAG
GNB1: 5'-CGGAACTCAGCTGGAAAGACA, 3'-AAC-
GAAGTCAAGAAGGCCACA
BDNF: 5'-AGCCCAACAACTTTCCCTT, 3'-GAGAG
CTCGGCTTACACAGG
Quantitative Real Time PCR
Quantitation of DNA extracted from three independent
ChIP experiments was done by real time PCR using prim-
ers targeting the promoter regions of the following genes
- BDNF, CRMP1, Clusterin, GNB1 and Dynamin1. TheGibson et al. BMC Neuroscience 2010, 11:53
http://www.biomedcentral.com/1471-2202/11/53
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data were analyzed by the 7500 Fast Software (Applied
Biosystems). Quantification was performed using the
comparative CT method and is reported as the n-fold dif-
ference in antibody bound chromatin normalized against
the input DNA (Figure 5).
Cytochrome c oxidase assays
The method used for assaying cytochrome c oxidase
activity (COX) has been previously described [50]. COX
activity was determined as a first order rate constant and
expressed as rate/minute/mg protein. The assay was per-
formed at 550 nm and follows the decrease in absorbance
resulting from the oxidation of reduced cytochrome c
after addition of sample. Reduced cytochrome c was pre-
pared as per Trounce et al. [51].
Citrate synthase is a nuclear encoded enzyme of the tri-
carboxylic acid (TCA) cycle, located in the mitochondrial
matrix. Its activity was assayed and used to normalize
measured respiratory chain enzyme activity [51].
Mann-Whitney U non-parametric analysis was used to
determine the statistical significance in COX and citrate
synthase enzyme differences between MeCP2 knock-
down and control cells.
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